On Tuesday, Canaccord Genuity adjusted its outlook on Castle Biosciences (NASDAQ:CSTL), increasing the price target to $42.00 from the previous $35.00, while reiterating a Buy rating on the stock. The firm's analyst highlighted Castle's strong performance in the third quarter of 2024, noting an estimated revenue of $81.7 million, a 33% year-over-year increase. This figure surpasses the FactSet consensus estimate of $79.8 million.
The revenue surge for the quarter is attributed mainly to the sales of DecisionDx-Melanoma and DecisionDx-SCC tests. The company's other diagnostic tests, including IDgenetix and TissueCypher, are also believed to have contributed to the revenue boost.
The firm noted that Castle Biosciences assumed coverage for DecisionDx-SCC through the end of the third quarter of 2024, despite uncertainties regarding future reimbursement coverage.
Additionally, the reported total test volume for Castle Biosciences showed a year-over-year increase of 3%. Operating expenses for the company were forecasted to have risen by 12% from the previous year, reaching $66.7 million.
Attention during the company's third-quarter earnings call will be directed towards volume growth, average selling price (ASP) fluctuations, and the company's commercial strategies, particularly concerning the acquired assets and the expansion of its Pittsburgh laboratory.
The analyst also mentioned the potential impact of any positive developments regarding Medicare coverage for DecisionDx-SCC. Although not highly probable, any favorable news on the progress of the Novitas LCD (Local Coverage Determination) could significantly influence Castle Biosciences' stock price.
In other recent news, Castle Biosciences reported a significant 74% increase in revenue for the second quarter of 2024, reaching $87 million. This surge was attributed to higher selling prices and increased test volumes across its product lines, including its core dermatology tests, DecisionDX-Melanoma and DecisionDX-SCC, as well as its gastroenterology and mental health franchises.
The company's gross margin rose to 80.7% from 73.5% in Q2 2023, and the quarter's net income was $8.9 million, a significant turnaround from a net loss of $18.8 million in Q2 2023. In light of these results, Castle Biosciences revised its full-year 2024 revenue guidance to between $275 million and $300 million.
In other updates, BTIG raised the price target on Castle Biosciences' stock to $40 from $35 while maintaining a Buy rating. This adjustment follows a recent investor call which provided insights into the value of Castle Biosciences' diagnostics tests. The BTIG analyst highlighted the potential for significant growth in the adoption of Castle Biosciences' TissueCypher test and Lucid (NASDAQ:LCID) Diagnostics' EsoGuard screening test.
Lastly, Castle Biosciences is currently engaging with Medicare contractor Palmetto regarding the non-coverage decision for its DecisionDX-SCC test and anticipates providing updates on its development initiatives by the year's end.
InvestingPro Insights
Castle Biosciences' recent financial performance aligns with the positive outlook presented by Canaccord Genuity. According to InvestingPro data, the company's revenue growth has been impressive, with a 71.67% increase in the last twelve months as of Q2 2024. This robust growth supports the analyst's projection of strong Q3 2024 performance.
InvestingPro Tips highlight that Castle Biosciences holds more cash than debt on its balance sheet and has liquid assets exceeding short-term obligations. These factors contribute to the company's financial stability as it continues to expand its diagnostic test portfolio and invest in growth initiatives.
The stock's performance has been noteworthy, with InvestingPro data showing a 148.09% price total return over the past year. This aligns with the InvestingPro Tip indicating a high return over the last year and that the stock is trading near its 52-week high.
While the company is not currently profitable, as noted by one of the InvestingPro Tips, its strong revenue growth and strategic positioning in the diagnostic market support Canaccord Genuity's optimistic price target revision.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for Castle Biosciences, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.